Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hinder

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Diabetes, Obesity & Metabolism|January 29, 2021
Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trialYanLing He, Alok Pachori, Ping Chen, et al.
Journal of Clinical Pharmacology|January 7, 2006
Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjectsAnne Paccaly, Annke Frick, Marie-Laure Ozoux, et al.
Thrombosis and Haemostasis|February 24, 2006
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acidMarkus Hinder, Annke Frick, Ronald Rosenburg, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2007
Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluidThomas P Lodise, Martina Kinzig-Schippers, George L Drusano, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 11, 2016
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese SubjectsYi Han, Surya Ayalasomayajula, Wei Pan, et al.
British Journal of Clinical Pharmacology|December 15, 2015
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjectsThomas H Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula, et al.
European Journal of Clinical Pharmacology|July 6, 2018
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjectsUwe Schuehly, Surya Ayalasomayajula, Jeppe Buchbjerg, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Diabetes Technology & Therapeutics|November 28, 2025
A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 DiabetesChantal Mathieu, Michelle Quinlan, Kristina Wagner, et al.
Diabetes, Obesity & Metabolism|July 15, 2021
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trialSusanne Tan, Stanislav Ignatenko, Frank Wagner, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|January 29, 2021
Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trialYanLing He, Alok Pachori, Ping Chen, et al.
Journal of Clinical Pharmacology|January 7, 2006
Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjectsAnne Paccaly, Annke Frick, Marie-Laure Ozoux, et al.
Thrombosis and Haemostasis|February 24, 2006
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acidMarkus Hinder, Annke Frick, Ronald Rosenburg, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2007
Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluidThomas P Lodise, Martina Kinzig-Schippers, George L Drusano, et al.
European Journal of Drug Metabolism and Pharmacokinetics|March 11, 2016
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese SubjectsYi Han, Surya Ayalasomayajula, Wei Pan, et al.
British Journal of Clinical Pharmacology|December 15, 2015
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjectsThomas H Langenickel, Chiaki Tsubouchi, Surya Ayalasomayajula, et al.
European Journal of Clinical Pharmacology|July 6, 2018
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjectsUwe Schuehly, Surya Ayalasomayajula, Jeppe Buchbjerg, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 25, 2021
A framework to guide dose & regimen strategy for clinical drug developmentOliver Sander, Baldur Magnusson, Inga Ludwig, et al.
Diabetes Technology & Therapeutics|November 28, 2025
A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 DiabetesChantal Mathieu, Michelle Quinlan, Kristina Wagner, et al.
Diabetes, Obesity & Metabolism|July 15, 2021
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trialSusanne Tan, Stanislav Ignatenko, Frank Wagner, et al.
Pageof 5